CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 4 Open-market buy Chief Scientific Officer bought 1,238 shares at $1.61 ($1,993)
- 4 Open-market buy Director bought 38,032 shares at an average $1.92 ($73,059)
- 4 Open-market buy Director bought 27,000 shares at an average $1.89 ($51,108)
- 4 Open-market buy Chief Executive Officer bought 15,985 shares at an average $1.88 ($30,020)
- 4 Open-market buy Chief Technology Officer bought 13,358 shares at an average $1.88 ($25,061)
- 4 Open-market buy Chief Financial Officer bought 5,568 shares at an average $1.80 ($10,002)
- 8-K Event Other events
- 8-K Event Regulation FD disclosure
- 4 Grant or award Chief Financial Officer acquired 90,877 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 195,906 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 90,877 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 58,479 shares (grant or award)
- 4 Grant or award See Remarks acquired 73,684 shares (grant or award)
- 8-K Event Regulation FD disclosure
- 8-K Event Other events
- 8-K Event Other events
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 16 of 22 · 422 filings